:quality(70)/arc-anglerfish-arc2-prod-cmg.s3.amazonaws.com/public/XERW35OHFTQWUGO3FL4MMTOQ34.jpg)
BOSTON (AP) - The drug developer Columbia Laboratories Inc. is adding two directors to its board.
The company said Monday that Frank Armstrong and Nikin Patel will become board members, while Martyn Davies will serve as an adviser.
Armstrong led medical science and innovation in the research and development department at Merck Serono and previously led worldwide product development at Bayer AG and the Worldwide Medical Organization at Zeneca. He also served as CEO of Fulcrum Pharma PLC and president and CEO of CuraGen Corp.
Davies and Patel are co-founders of Molecular Profiles Ltd., which was acquired by Columbia Laboratories this month.
Shares of Columbia finished at $7.72 on Friday. They have traded in a 52-week range of $4.41 to $9.84.
Cox Media Group
/cloudfront-us-east-1.images.arcpublishing.com/cmg/7QOJU3BNCJERBNKJC5LWTBYFLU.png)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/2DRBVTNXJBF3HDQ4ASNMVGSIQQ.jpg)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/P7OH7K23LFCNNIHTTKUQR4U3HA.jpeg)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/M7XLU5BEQVGPRNBJVTIE7BB464.jpeg)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/7QKIU6WUQVV2PVA5YE6CCCJANM.jpg)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/KZTG32TCTBAP7PGVE2HLFGHAHQ.jpg)